

August 8, 2018

Press Release

Teijin Ltd.
Yoshindo Inc.
YL Biologics Ltd.

Teijin, Yoshindo and YL Biologics Enter Into a Marketing Alliance Agreement for Etanercept Biosimilar, Anti-rheumatoid Arthritis Agent

Teijin Ltd. (Head office: Kita-ku, Osaka, President and CEO: Jun Suzuki), Yoshindo Inc. (Head Office: Toyama City, Toyama, President and Representative Director: Hiroki Kitamura) and YL Biologics Ltd. (Head office: Chuo-ku, Tokyo, President and Representative Director: Toshihiko Hibino) have announced that the three companies enter into a marketing alliance agreement for Etanercept biosimilar, anti-rheumatoid arthritis agent (Development code: YLB113).

YL Biologics has led the global phase III study enrolled over 500 rheumatoid arthritis patients and a half of them were recruited in Japan. Based on the results of phase III study, YL Biologics submitted NDA to PMDA in March, 2018. Although YL Biologics obtains active pharmaceutical ingredients of YLB113 from Lupin Ltd., an India based global pharmaceutical company, YL Biologics subcontracts manufacturing of it to AY Pharma Co. Ltd., a wholly owned subsidiary of Yoshindo and AY Pharma manufactures the final products in its plant located in Japan.

Teijin Pharma (Head Office: Chiyoda-ku, Tokyo, President and Representative Director: Akihisa Nabeshima) which is playing central role of health care business in Teijin group will jointly distribute and market YLB113 with Yoshindo in Japan according to the agreement. Teijin Pharma intends to contribute the healthier lives of rheumatoid arthritis patients and improve their quality of life through putting YLB113 on their product line-up and accordingly further strengthening “Bone and Joint Field” as Teijin Pharma’s expertise area.

Yoshindo manufactures generic drugs with high quality and reasonable prices through its systems with research and development, manufacturing and sales and marketing. At present, Yoshindo is accelerating manufacturing and sales activities for essential drugs such as infusion and dialysis fluid, and advancing research and development into biopharmaceuticals. Yoshindo is building new technologies and know-how, with the aim of remaining an irreplaceable pharmaceutical company for Japan moving into the future.

YL Biologics is committed to take the biosimilar products with high medical needs as the targets for the pipeline and effectively develop them by making good use of the company's rich know-how. YL biologics will contribute to the society and people through stably providing its products to the medical field around the world.

For further information, please contact:

Teijin Ltd. Corporate Communications Department
Tel: 03-3506-4055

Yoshindo Inc. Biopharmaceutical Sales Department
Tel: 03-6667-5881

YL Biologics Ltd. Liaison & Business Development Department
Tel: 03-6667-5900